Neuroprotective products, also called as neuroprotective agents are medications that aid in the protection of brain neurons from injury and early degeneration of neuron cells. Neuroprotective products are useful in the treatment of various central nervous system (CNS) degeneration ailments such as Alzheimer’s diseases, Parkinson’s diseases, Huntington’s disease, traumatic brain injuries, etc.
Neurodegeneration is a progressive disorder in which loss of neuronal structure and dysfunction results in neuronal cell death. Neurodegeneration is common in various diseases affecting the CNS such as Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Thus, neurodegenerative disease is termed for range of neurological disorders which primarily affects the neurons in the CNS and results in death of neuronal cell gradually, thereby leading to loss of brain functions such as memory, movement and cognition. Growing geriatric population is one of the most important factors for the growth of the market as neurodegenerative disorders are often associated with aging. According to World Population Prospects 2019 by United Nations, 1 in 11 people in the world were above the age of 65 in 2019 which will grow to 1 in 6 people by 2050. In total, there were around 703 million people aged 65 or more in the world in 2019 and the number is projected to reach to 1.5 billion in 2050. The increase in the elderly population will be proportional with the rise in neurological diseases in the age group as per the Dijon Stroke Registry. The report also states that there will be around 55% increase in the total number of stroke case by 2030, majorly driven by the cases affecting elderly people aged 65 and above. Dementia also showed incidence similar to stroke, with closely correlation with age. The aging populations will also drive the burden of amyotrophic lateral sclerosis in the coming years as the peak of incidence is around the age of 75.
Strategic business expansion activities by government bodies in order to increase the research and knowledge and enhance the product portfolio by innovative product launch is positively impacting the growth of the neuroprotective product's market. In 2021, the United States National Institute of Health united with private-sector partners for Accelerating Medicine Partnership for Alzheimer’s Disease (AMP AD) program. The latter have committed to spend US$ 74.9 million over the next five years in the newly announced second phase of the program. However, high failure rate of clinical studies for neurological disorders and high cost involved in the R&D will hamper the growth of the neuroprotective product's market in the coming years.
Segment Analysis by Region
In 2019, North America held the largest share in the global neuroprotective products market and is projected to continue to exhibit similar trend during the forecast period. Presence of large number of players operating in the region and high healthcare expenditure drives the region. The U.S. accounted for largest share in the North America market owing to high prevalence of neurodegenerative disorders and high awareness about the same. For instance, the incidence of Alzheimer’s is growing at a fast rate in US with more than 6 million people of all ages having the disease. To be precise, an estimated 6.2 million people aged 65 or older are living with Alzheimer’s dementia in 2021 and above 72% of these are age 75 or older. The market in Asia Pacific is expected to witness faster growth in the target market due to substantial increase in patients suffering from aging population. In addition, major players approach towards enhancing the business in emerging economies through strategic merger is expected to boost the growth of regional market.
The global neuroprotective products market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition. The companies operating in the market include F. Hoffman La-Roche, Novartis AG, Pfizer Inc., Genervon Biopharmaceuticals, Merck & Co. Inc., NeuroVive Pharmaceutical, Neuren Pharmaceuticals, Bionure Inc., BHRPharma LLC, among others.
Global Neuroprotective Products Market
2016 – 2030
2021 – 2030
Drug Class, Indication, and Geography
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling,
Neuroprotective Products Market Segment Analysis, 2019
The global neuroprotective products market is segmented into drug class and indication. The drug class segment is bifurcated into cholinesterase inhibitors, NMDA receptor antagonist, anti-inflammatory & anti-apoptotic agents, neurotrophic factors, mitochondrial dysfunction regulators, metal ion chelators, ion channel modulators, free radical trappers, anti-and others. Among drug class, the cholinesterase inhibitors are expected to witness faster growth in the neuroprotective product's market. The indication segment is divided into Parkinson’s disease, Alzheimer's disease, Multiple sclerosis, Ocular degeneration (retinal disorders), Amyotrophic lateral sclerosis (ALS), Stroke, Huntington's disease, Neuropathies, and Brain injury. Among neuroprotective products, the Stroke segment is expected to account for a major revenue share in the global market.
Market By Drug Class
NMDA receptor antagonists
Anti-inflammatory and anti-apoptotic agents
Mitochondrial dysfunction regulators
Metal Ion Chelators
Ion channel modulators
Free radical trappers
Anti excitotoxic agents
Market By Indications
Eosinophilic Airway Inflammation
Ocular degeneration (retinal disorders)
Amyotrophic lateral sclerosis (ALS)
Stroke, Huntington's disease
Market By Geography
• Rest of Europe
• South Korea
• Rest of Asia-Pacific
• Rest of Latin America
Middle East & Africa
• South Africa
• Rest of Middle East & Africa
Growing geriatric population and growing prevalence of neurodegenerative diseases globally is the major factors driving the neuroprotective products market
In drug class segment the cholinesterase inhibitors segment is growing at faster pace.
In the global market the Asia Pacific region is expected to grow faster.
The companies operating in the market include F. Hoffman La-Roche, Novartis AG, Pfizer Inc., Genervon Biopharmaceuticals, Merck & Co. Inc., NeuroVive Pharmaceutical, Neuren Pharmaceuticals, Bionure Inc., BHRPharma LLC, among others.
The North America is expected to account for major revenue share in the global market.
In indication the Alzheimer’s segment is growing at faster pace.
High failure rate of clinical studies for neurological disorders and high cost involved in the R&D will hamper the growth of the neuroprotective products market in the coming years.